You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. Please disable any ad blockers and view the site in non-private mode.
For in vitro diagnostic use. Others Elecsys free PSA IVD Elecsys® free PSA CPS_000471 08828601190 free PSA Elecsys cobas e 100 V3 Elecsys free PSA 07613336166611 Reagents, kits 100 tests cobas e 411/601/602 true 08828610190 free PSA Elecsys E2G 300 V2 Elecsys free PSA 07613336166628 Reagents, kits 300 tests cobas e 402/801 true 08828601500 Elecsys free PSA en 4 FF00000004646E0E FF0000000392320E 08828601190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08828610500 Elecsys free PSA en 5 FF000000053E9B0E FF0000000452FB0E 08828610190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08828610500 Elecsys free PSA en 6 FF00000005A1820E FF00000005A1820E 08828610190 08828610214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of free prostate‑specific antigen in human serum and plasma.This assay is indicated for measurement of fPSA in conjunction with the Elecsys total PSA assay to develop a ratio (% fPSA) of fPSA to tPSA. This ratio is useful when used in conjunction with the Elecsys total PSA test as an aid in distinguishing prostate cancer from benign prostatic conditions in men age 50 years or older who have a digital rectal examination (DRE) that is not suspicious for prostate cancer and an Elecsys total PSA value in the range 4 ng/mL to 10 ng/mL. Prostate biopsy is required for the diagnosis of prostate cancer.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en